Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory B-cell Malignancies

NCT05410041 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Acute Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Non Hodgkin Lymphoma

Interventions

BIOLOGICAL: CAR-NK-CD19 Cells

Sponsor

Beijing Boren Hospital